Pneumococcal Conjugate Vaccine (7-Valent)

Table of contents

  • Brand Names
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage

Brand Names


Austria: Prevnar; Belgium: Pneumo 23, Prevenar; Czech Republic: Pneumo 23, Prevenar, Synflorix; Estonia: Pneumo 23, Prevenar, Synflorix; Finland: Pneumovax, Prevenar, Synflorix; France: Prevenar, Prevnar, Synflorix; Germany: Prevenar, Synflorix; Greece: Pneumovax 23, Pnu Imune, Prevenar, Synflorix; Hungary: Prevenar; Ireland: Pneumovax, Prevenar, Synflorix; Italy: Prevenar, Synflorix; Latvia: Prevenar; Lithuania: Pneumo 23, Prevenar, Synflorix; Malta: Prevenar; Netherlands: Pneumo 23, Prevenar, Synflorix; Poland: Pneumovax 23, Prevenar, Synflorix; Portugal: Pneumo 23, Penumovax 23, Prevenar, Synflorix; Romania: Pneumo 23, Prevenar, Synflorix; Slovakia: Pneumo 23, Prevenar, Synflorix; Slovenia: Prevenar; Spain: Pneumo 23; Sweden: Pneumo 23, Pneumovax, Prevenar, Synflorix; UK: Prevenar, Synflorix.

North America

Canada: Pneumo 23, Pneumovax 23, Prevnar, Synflorix.

Latin America

Argentina: Prevenar; Brazil: Vacina Pneumocócica Conjugada 7-Valente; Mexico: Prevenar.


Japan: Pneumovax.

Drug combinations


Pharmacologic Category

Serums, Toxoids, and Vaccines; Vaccines; Inactivated Bacterial Vaccine. (ATC-Code: J07AL).

Mechanism of action

Promotes active immunization against invasive disease caused by S. pneumoniae capsular serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, all of which are individually conjugated to CRM197 protein.

Therapeutic use

Immunization of infants and toddlers against Streptococcus pneumoniae infection, or otitis media, caused by serotypes included in vaccine.

Pregnancy and lactiation implications

Unlabeled use


Hypersensitivity to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid.

Warnings and precautions

Anaphylactoid/hypersensitivity reactions might occur. Immunization should be delayed during the course of acute severe febrile illness. May be administered in acute illness (with or without fever). Use of pneumococcal conjugate vaccine does not replace use of 23-valent pneumococcal polysaccharide vaccine in children ≥24 months of age with asplenia, chronic illness, HIV infection, sickle cell disease, or who are immunocompromised. Use with caution in history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy (bleeding/hematoma may occur from I.M. administration). Not to be used to treat pneumococcal infections or to provide immunity against diphtheria. Febrile seizures reported (rare). Use with caution in severely immunocompromised patients (may have reduced response to vaccination). Packaging may contain natural latex rubber.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart